X0508 4 2023-09-19 0 0001885522 Neumora Therapeutics, Inc. NMRA 0001769012 ARCH Venture Partners X, LLC 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 0 0 1 0 0001979548 ARCH Venture Partners XII, LLC 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 0 0 1 0 0001979765 ARCH Venture Partners XII, L.P. 8755 W. HIGGINS ROAD , SUITE 1025 CHICAGO IL 60631 0 0 1 0 0001906837 ARCH Venture Fund XII, L.P. 8755 W. HIGGINS ROAD , SUITE 1025 CHICAGO IL 60631 0 0 1 0 0001219039 CRANDELL KEITH 8755 W. HIGGINS ROAD , SUITE 1025 CHICAGO IL 60631 0 0 1 0 0001229592 GILLIS STEVEN 8755 W. HIGGINS ROAD , SUITE 1025 CHICAGO IL 60631 0 0 1 0 0001219042 NELSEN ROBERT 8755 W. HIGGINS ROAD , SUITE 1025 CHICAGO IL 60631 0 0 1 0 0001219043 BYBEE CLINTON 8755 W. HIGGINS ROAD , SUITE 1025 CHICAGO IL 60631 0 0 1 0 0 Common Stock 2023-09-19 4 C 0 684167 A 684167 I By ARCH Venture Fund VII, L.P. Common Stock 2023-09-19 4 C 0 1144973 A 1144973 I By ARCH Venture Fund VIII Overage, L.P. Common Stock 2023-09-19 4 C 0 6895021 A 12205379 I By ARCH Venture Fund X, L.P. Common Stock 2023-09-19 4 C 0 6576400 A 11886758 I By ARCH Venture Fund X Overage, L.P. Common Stock 2023-09-19 4 C 0 2124143 A 2124143 I By ARCH Venture Fund XII, L.P. Common Stock 2023-09-19 4 P 0 1500000 17.00 A 3624143 I By ARCH Venture Fund XII, L.P. Series A-1 Preferred Stock 2023-09-19 4 C 0 684167 D Common Stock 684167 0 I By ARCH Venture Fund VII, L.P. Series A-1 Preferred Stock 2023-09-19 4 C 0 1144973 D Common Stock 1144973 0 I By ARCH Venture Fund VIII Overage, L.P. Series A-2 Preferred Stock 2023-09-19 4 C 0 6895021 D Common Stock 6895021 0 I By ARCH Venture Fund X, L.P. Series A-2 Preferred Stock 2023-09-19 4 C 0 6576400 D Common Stock 6576400 0 I By ARCH Venture Fund X Overage, L.P. Series B Preferred Stock 2023-09-19 4 C 0 2124143 D Common Stock 2124143 0 I By ARCH Venture Fund XII, L.P. The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LP and AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. Each of AVP VII LP, AVP VII LLC and the AVP VII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. Represents shares held directly by ARCH Venture Fund VIII Overage, L.P. (ARCH VIII Overage). ARCH Venture Partners VIII, LLC (AVP VIII LLC) is the general partner of ARCH VIII Overage. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VIII LLC (the AVP VIII LLC Managing Directors). AVP VIII LLC may be deemed to beneficially own the shares held by ARCH VIII Overage, and each of the AVP VIII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VIII Overage. Each of AVP VIII LLC and the AVP VIII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X. Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage. ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. Each of AVP X LP, AVP X Overage LP, AVP X LLC and the AVP X Committee Members disclaims beneficial ownership of such shares except to the extent of their pecuniary interest therein, if any. Represents shares held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. This Form 4 is filed jointly by ARCH X, AVP X LP, ARCH X Overage, AVP X Overage LP, AVP X LLC, ARCH VII, AVP VII LP, AVP VII LLC, ARCH VIII Overage, AVP VIII LLC, ARCH XII, AVP XII LP, AVP XII LLC, Robert Nelsen, Steven Gillis, Keith Crandell, Clinton Bybee (collectively, the "Reporting Persons"). Kristina Burow has direct ownership of Series A-1 Preferred Stock and is filing her own Form 4 separately. Form 2 of 2 ARCH VENTURE FUND X, L.P.; By: ARCH Venture Partners X, L.P, Its: General Partner; By: ARCH Venture Partners X, LLC, Its: General Partner; By: /s/ Mark McDonnell, attorney-in-fact 2023-09-19 ARCH VENTURE FUND X OVERAGE, L.P.; By: ARCH Venture Partners X Overage, L.P., Its: General Partner; By: ARCH Venture Partners X, LLC, Its: General Partner; By: /s/ Mark McDonnell, attorney-in-fact 2023-09-19 ARCH VENTURE FUND VII, L.P.; By: ARCH Venture Partners VII, L.P., Its: General Partner; By: ARCH Venture Partners VII, LLC, Its: General Partner; By: /s/ Mark McDonnell, attorney-in-fact 2023-09-19 ARCH VENTURE FUND VIII OVERAGE, L.P.; By: ARCH Venture Partners VIII, LLC, Its General Partner; By: /s/ Mark McDonnell, attorney-in-fact 2023-09-19 ARCH VENTURE FUND XII, L.P.; By: ARCH Venture Partners XII, L.P., Its General Partner; By: ARCH Venture Partners XII, LLC., Its General Partner; By: /s/ Mark McDonnell, attorney-in-fact 2023-09-19 Keith Crandell, Managing Director, By: /s/ Mark McDonnell, as Attorney-in-Fact 2023-09-19 Steven Gillis, Managing Director, By: /s/ Mark McDonnell, as Attorney-in-Fact 2023-09-19 Robert Nelsen, Managing Director, By: /s/ Mark McDonnell, as Attorney-in-Fact 2023-09-19 Clinton Bybee, Managing Director, By: /s/ Mark McDonnell, as Attorney-in-Fact 2023-09-19